Response to Comments: MolDX: Pharmacogenomics Testing

This document (A58237) is a response to public comments on the MolDX: Pharmacogenomics Testing LCD L38335 and does not itself define coverage criteria. Refer to LCD L38335 for specific indications, limitations, documentation requirements, and frequency limits; the notice period began 07/02/2020 and the LCD became effective 08/17/2020.

"This document is a response-to-comments notice for MolDX: Pharmacogenomics Testing LCD L38335; for definitive coverage criteria, see the MolDX L38335 LCD text rather than this response document."

Sign up to see full coverage criteria, indications, and limitations.